SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 59.26 |
| Enterprise Value ($M) | 57.84 |
| Book Value ($M) | 10.93 |
| Book Value / Share | 0.73 |
| Price / Book | 5.42 |
| NCAV ($M) | -6.96 |
| NCAV / Share | -0.47 |
| Price / NCAV | -8.52 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.57 |
| Return on Assets (ROA) | -0.24 |
| Return on Equity (ROE) | -0.90 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.03 |
| Current Ratio | 1.38 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 46.16 |
| Assets | 64.04 |
| Liabilities | 53.12 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Tang Capital Management Llc | 7.30 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 19,771 | 76,033 | 26.00 | |
| 5,496 | 23,322 | 23.57 | |
| 2,166 | 21,310 | 10.16 | |
| 3,461 | 13,326 | 25.97 | |
| 11,475 | 44,213 | 25.95 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CYRX – Cryoport, Inc. | CYTH – Cyclo Therapeutics, Inc. |
| DARE – Daré Bioscience, Inc. | DMAC – DiaMedica Therapeutics Inc. |
| DNTH – Dianthus Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io